- Home
- CCIX vs KMDA Comparison
CCIX vs KMDA Comparison
Compare CCIX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIX
- KMDA
- Stock Information
- Founded
- CCIX 2023
- KMDA 1990
- Country
- CCIX United States
- KMDA Israel
- Employees
- CCIX N/A
- KMDA N/A
- Industry
- CCIX
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CCIX
- KMDA Health Care
- Exchange
- CCIX Nasdaq
- KMDA Nasdaq
- Market Cap
- CCIX 386.4M
- KMDA 410.6M
- IPO Year
- CCIX 2024
- KMDA N/A
- Fundamental
- Price
- CCIX $10.49
- KMDA $6.83
- Analyst Decision
- CCIX
- KMDA Strong Buy
- Analyst Count
- CCIX 0
- KMDA 2
- Target Price
- CCIX N/A
- KMDA $13.00
- AVG Volume (30 Days)
- CCIX 45.6K
- KMDA 48.8K
- Earning Date
- CCIX 11-07-2013
- KMDA 11-12-2025
- Dividend Yield
- CCIX N/A
- KMDA 2.85%
- EPS Growth
- CCIX N/A
- KMDA 27.97
- EPS
- CCIX 0.28
- KMDA 0.32
- Revenue
- CCIX N/A
- KMDA $169,517,000.00
- Revenue This Year
- CCIX N/A
- KMDA $14.49
- Revenue Next Year
- CCIX N/A
- KMDA $10.12
- P/E Ratio
- CCIX $37.07
- KMDA $21.30
- Revenue Growth
- CCIX N/A
- KMDA 9.67
- 52 Week Low
- CCIX $10.01
- KMDA $5.17
- 52 Week High
- CCIX $11.66
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- CCIX 39.67
- KMDA 38.01
- Support Level
- CCIX $10.45
- KMDA $6.90
- Resistance Level
- CCIX $10.58
- KMDA $7.27
- Average True Range (ATR)
- CCIX 0.05
- KMDA 0.18
- MACD
- CCIX -0.00
- KMDA -0.00
- Stochastic Oscillator
- CCIX 38.46
- KMDA 2.42
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.